Dr. Namrata Vijavergia
Claim this profileStudies Small Cell Lung Cancer
Studies Neuroendocrine Carcinoma
1 reported clinical trial
2 drugs studied
More about Namrata Vijavergia
Clinical Trial Related2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments Namrata Vijavergia has experience with
- Iadademstat
- Paclitaxel
Breakdown of trials Namrata Vijavergia has run
Small Cell Lung Cancer
Neuroendocrine Carcinoma
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Namrata Vijavergia specialize in?
Namrata Vijavergia focuses on Small Cell Lung Cancer and Neuroendocrine Carcinoma. In particular, much of their work with Small Cell Lung Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Namrata Vijavergia currently recruiting for clinical trials?
No, Namrata Vijavergia is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Namrata Vijavergia has studied deeply?
Yes, Namrata Vijavergia has studied treatments such as Iadademstat, Paclitaxel.
What is the best way to schedule an appointment with Namrata Vijavergia?
Apply for one of the trials that Namrata Vijavergia is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.